Pharmaceuticals

Seuraa

Pfizer stock rises after aligning with Trump on drug pricing

01. lokakuuta 2025 Raportoinut AI

Pfizer's shares climbed on Monday after the company expressed support for former President Donald Trump's proposal to allow imports of lower-priced drugs from Canada. This stance marks a shift for the pharmaceutical giant, which has historically opposed such measures. The move comes amid ongoing debates over U.S. drug costs.

Lawsuits claim Tylenol use in pregnancy causes autism

02. lokakuuta 2025 Raportoinut AI

More than 100 lawsuits have been filed against acetaminophen manufacturers, including Johnson & Johnson, alleging that the drug's use during pregnancy increases the risk of autism and ADHD in children. These legal actions stem from scientific studies showing associations between prenatal exposure and neurodevelopmental disorders. The cases highlight growing concerns over the safety of a widely used pain reliever.

EMA Panel Recommends Approval for Merck's Injectable Keytruda

A key committee of the European Medicines Agency has recommended approval for an injectable version of Merck's cancer drug Keytruda, paving the way for potential authorization across the European Union. This subcutaneous formulation aims to offer a more convenient alternative to intravenous administration for patients with various cancers. The recommendation, issued on September 19, 2025, follows positive clinical data and could enhance treatment accessibility in Europe.

AstraZeneca Cuts Prices on Select US Drugs After Trump Pressure

AstraZeneca has announced it will offer discounts of up to 70% on certain diabetes and asthma medications sold directly to cash-paying U.S. patients, responding to demands from President Donald Trump for lower drug prices. The move aligns these prices with those paid by Medicare and marks the company as the latest in the pharmaceutical industry to adjust amid ongoing regulatory scrutiny. This development underscores the intensifying focus on drug affordability in the United States under the current administration.